EWTX Edgewise Therapeutics, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
19:29
Sep 07
Sep 07
The author notes EWTX stands out to them in a reply.
The author notes EWTX stands out to them in a reply, but provides no explicit position or directional call.
LOW
23:48
Aug 18
Aug 18
The author suggests EWTX could move if a technical boulder signal resolves.
The author suggests EWTX could move if a technical boulder signal resolves, but the language is conditional and not a committed position.
LOW
12:58
Aug 17
Aug 17
Reports largest aggregate Q2 fund holdings
"Reports largest aggregate Q2 2026 holdings across 95 specialist funds based on 13F filings, no directional view."
MED
12:50
Aug 17
Aug 17
Reports most reduced positions across funds
"Reports most reduced positions across specialist funds in Q2 2026 excluding M&A take-outs, no directional view."
MED
12:31
Aug 17
Aug 17
Notes large aggregate Q2 fund holdings
Notes the stock is among the largest aggregate Q2 holdings across 93 funds based on 13F filings.
MED
11:53
Aug 17
Aug 17
Reports most reduced positions by specialist funds
Reports the most reduced positions by specialist funds in Q2 2026, excluding M&A takeouts.
MED
17:25
Aug 10
Aug 10
Highlights past successful biotech valuation calls.
Author lists numerous biotech and pharma tickers as past successful valuation calls, offering no current directional view.
LOW
01:04
Aug 10
Aug 10
Author details a biotech portfolio with explicit long positions in ABVX and NKTR.
Author details a biotech portfolio with explicit long positions in ABVX and NKTR, bullish conviction on IVA and TENX upside potential, while watching VERA and XBI for catalysts.
13:53
Aug 04
Aug 04
Author notes FOMO-driven gains in EWTX and COGT tied to a Boulder connection.
Author notes FOMO-driven gains in EWTX and COGT tied to a Boulder connection, but describes price action without stating a position or forward call.
LOW
23:02
Aug 03
Aug 03
Four biotechs flagged as potential buyout targets
Author flags VRDN, OKUR, ELVN, and EWTX as potential acquisition targets based on Novartis Denver flight activity; notes ELVN HQ move and suspicious price action, but no directional commitment.
LOW
22:56
Aug 03
Aug 03
Denver flights flag potential biotech M&A targets
Flags four biotechs as possible M&A targets from Novartis's unusual Denver flight activity; notes ELVN is the one already moving.
LOW
17:40
Jun 28
Jun 28
Author increased their ABVX position as a concentrated conviction bet on Obe commercialization.
Author increased their ABVX position as a concentrated conviction bet on Obe commercialization at ~$8B market cap, while closing COGT and BCRX for decent returns, and notes XBI outperformance as a positive sector signal.
LOW
00:00
Jun 24
Jun 24
Author explicitly closed EWTX position; listed under "Closed" in weekly portfolio update.
Author explicitly closed EWTX position; listed under "Closed" in weekly portfolio update despite remaining constructive on the story longer-term.
MED
12:00
Jun 16
Jun 16
SpaceX rises 7.3% in premarket, Mag 7 stocks are mixed, Domo drops 13% on strategic review.
SpaceX rises 7.3% in premarket, Mag 7 stocks are mixed, Domo drops 13% on strategic review, Edgewise falls 23% on trial results, Edwards Lifesciences gains 3.1% on coverage proposal, Huntsman drops 7% on merger with Olin, and Robinhood gains 2% on workforce reduction.
18:11
Jun 12
Jun 12
Hold/long EWTX; author retains position despite mixed sentiment post-Seva news.
Hold/long EWTX; author retains position despite mixed sentiment post-Seva news, dismisses afib concern as overstated, and sees CV exposure making it a BP acquisition target — though conviction is lower than other holdings.
MED
21:57
Jun 06
Jun 06
Author is holding EWTX into an imminent data readout (n=7500 dataset expected this month) that.
Author is holding EWTX into an imminent data readout (n=7500 dataset expected this month) that could serve as a near-term price catalyst; considered selling but chose to maintain position.
MED
12:36
Jun 01
Jun 01
Buy EWTX — author discloses an ongoing long position.
Buy EWTX — author discloses an ongoing long position, citing a better-than-expected Seva deal that exceeded their valuation estimates, leaving EWTX as a cleaner, focused cardio pure-play.
MED
18:19
May 19
May 19
Author adds to ABVX and NKTR positions ahead of key data.
Author adds to ABVX and NKTR positions ahead of key data, expressing bullish conviction on ABVX's high probability of meeting endpoints while holding other biotech names for later review.
HIGH
17:44
May 07
May 07
Long EWTX, a biotech holding with conviction from the speaker's due diligence.
HIGH
16:41
May 05
May 05
Seedy19 expresses a personal preference for EWtx over another ticker.
Seedy19 expresses a personal preference for EWtx over another ticker, indicating a bullish directional view on EWtx.
HIGH
16:35
May 05
May 05
Re-enter long $EWTX as part of a cardiovascular-biotech pair.
Re-enter long $EWTX as part of a cardiovascular-biotech pair, citing overdue exposure and a current buying opportunity.
HIGH
About EWTX Analyst Coverage
Buzzberg tracks EWTX (Edgewise Therapeutics, Inc.) across 2 sources. 6 bullish vs 0 bearish calls from 2 analysts. Sentiment: predominantly bullish (29%). 21 total trade ideas tracked. Past 7 days: 1 watch. Latest voices: seedy19tron, zerohedge.